Form 10-Q CASI Pharmaceuticals, For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
CASI Pharmaceuticals (CASI) PT Raised to $6 at Oppenheimer
August 13, 2021 9:21 AM EDTOppenheimer analyst Leland Gershell raised the price target on CASI Pharmaceuticals (NASDAQ: CASI) to $6.00 (from $5.00) while maintaining an Outperform rating.
The analyst commented, "CASI reported another quarter of solid Evomela growth, posting 2Q21 revenue of $7.1M (+25% Q/Q, +173% Y/Y) vs. our $6.2M... More



